D0101-01
Clone Type
MonoclonalHost
MouseSource
HumanIsotype
IgG2b,kClone Number
4H74 (97A1015)Grade
Affinity PurifiedApplications
FC IHC IP WBCrossreactivity
Hu MoShipping Temp
Blue IceStorage Temp
-20°CMouse Anti-D4-GDI (D4 GDP-Dissociation Inhibitor)
D4-GDI (GDP dissociation inhibitor) is a negative regulator of the ras-related Rho family of GTPases. Since the Rho GTPases promote cytoskeletal and membrane changes associated with apoptotic cell death, the removal of the D4-GDI block through its cleavage is important for inducing apoptosis. Caspase-3 cleaves the 28kD mature form of D4-GDI to give a 23kD and 5kD size fragment. The 23kD fragment then translocates to the nucleus. The mechanisms involving cleavage of D4-GDI with apoptosis are not presently known. Activation of the Jun N-terminal kinase, a regulator of apoptosis, may be one of the mechanisms.
Applications
Suitable for use in Western Blot, Immunoprecipitation, Flow Cytometry and Immunohistochemistry. Other applications not tested.
Recommended Dilutions
Western Blot: 0.1-1ug/ml Immunoprecipitation: 1-2ug/ml Flow Cytometry: 0.5-1ug/1x10e6 cells Immunohistochemistry (Paraffin): 5ug/ml Optimal dilutions to be determined by the researcher.
Storage and Stability
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
Immunogen
Synthetic peptide corresponding to the region of the Fas-induced cleavage site of human D4-GDI.
Form
Supplied as a liquid in PBS, 0.05% BSA, 0.05% sodium azide.
Purity
Purified by Protein G affinity chromatography.
Specificity
Recognizes cleavage specific human D4-GDI. Species Crossreactivity: mouse.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
References
1. Na S, et al. J Biol Chem. 271:11209-13 (1996). 2. Krieser RJ, et al. Cell Death Differ 6:412-9 (1999). 3. Yamaguchi, H., et al. Oncogene 20: 7779-7786 (2001). 4. Saori Sato, Naoya Fujita, Takashi Tsuruo. Oncogene 21, 1727-1738 (2002). 5. John J. Gildea, et al. Cancer Res. 62: 6418-6423 (2002). 6. Hirohito Yamaguchi, et al. Cancer Res., 62: 466-471 (2002). 7. Sandy M. Cuddeback, et al. J. Biol. Chem, 276: 20559-20565 (2001). 8. Yen-Chou Chen, et al. Biochemical Pharmacology 64: 1713-1724 (2002). 9. Yen-Chou Chen, et al. Biochem Pharmacol, 66(7): 1139-1150 (2003). 10. Shing-Chuan Shen, et al. J Cell Biochem, 89: 1044-1055 (2003). 11. Chun-Yi Liu, et al. Ann. N.Y. Acad. Sci 1011: 133-145 (2004). 12. Christopher E. Jenkins, et al. J. Biol. Chem., 279: 37201-37207 (2004). 13. Ching Huai Ko, et al. Free Radical Biology & Medicine, 36 (7): 897-910 (2004). 14. Christopher E. Jenkins, et al. J. Immunol., 177: 8000-8007 (2006). 15. Hu LD, et al. Oncology Rep 17:138301389 (2007).USBio References
No references available